Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo

Lan Feng1 Division of Molecular Pharmaceutics, Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, NC, USA

Huali Wu2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, NC, USA

Ping Ma1 Division of Molecular Pharmaceutics, Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, NC, USA

Russell J Mumper1 Division of Molecular Pharmaceutics, Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, NC, USA;3 UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, USA

S Rahima Benhabbour1 Division of Molecular Pharmaceutics, Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, NC, USACorrespondence[email protected]

Pages 2545-2556 | Published online: 21 Oct 2011

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

GoldspielBRClinical overview of the taxanesPharmacotherapy1997175 Pt 2110S125S9322878
PubMed Web of Science ®Google Scholar
van OosteromATSchrijversDSchrijversDDocetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experienceAnticancer Drugs1995633563687670133
PubMed Web of Science ®Google Scholar
CortesJEPazdurRDocetaxelJ Clin Oncol19951310264326557595719
PubMed Web of Science ®Google Scholar
RingelIHorwitzSBStudies with RP 56976 (taxotere): a semisynthetic analogue of taxolJ Natl Cancer Inst19918342882911671606
PubMedGoogle Scholar
ExtraJMRousseauFBrunoRClavelMLe BailNMartyMPhase I and pharmacokinetic study of Taxotere (RP56976;NSC 628503) given as a short intravenous infusionCancer Res1993535103710428094996
PubMed Web of Science ®Google Scholar
BissettDSetanoiansACassidyJPhase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusionCancer Res19935335235278093854
PubMed Web of Science ®Google Scholar
BurrisHIrvinRKuhnJPhase-I clinical-trial of taxotere administered as either a 2-hour or 6-hour intravenous-infusionJ Clin Oncol19931159509588098059
PubMed Web of Science ®Google Scholar
PazdurRNewmanRANewmanBMPhase I trial of Taxotere: five-day scheduleJ Natl Cancer Inst19928423178117881359154
PubMed Web of Science ®Google Scholar
TomiakEPiccartMJKergerJPhase-I study of docetaxel administered as a 1-hour intravenous-infusion on a weekly basisJ Clin Oncol1994127145814677912725
PubMed Web of Science ®Google Scholar
CuiZRYanasarnNSloatBRNanoparticles engineered from lecithin-in- water emulsions as a potential delivery system for docetaxelInt J Pharmaceut20093791174180
Web of Science ®Google Scholar
KhalidMNSimardPHoarauDDragomirALerouxJCLong circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumorsPharm Res200623475275816550475
PubMed Web of Science ®Google Scholar
XuZChenLGuWThe performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinomaBiomaterials200930222623218851881
PubMed Web of Science ®Google Scholar
ElsabahyMPerronMEBertrandNYuGELerouxJCSolubilization of docetaxel in poly(ethylene oxide)-block-poly(butylene/styrene oxide) micellesBiomacromolecules2007872250225717579476
PubMed Web of Science ®Google Scholar
ImmordinoMLBrusaPArpiccoSStellaBDosioFCattelLPreparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxelJ Control Release200391341742912932719
PubMed Web of Science ®Google Scholar
StraubingerRMBalasubramanianSVPreparation and characterization of taxane-containing liposomesMethods Enzymol20053919711715721376
PubMed Web of Science ®Google Scholar
IsacchiBArrigucciSMarcaGLConventional and long-circulating liposomes of artemisinin: preparation, characterization, and pharmacokinetic profile in miceJ Liposome Res201121323724421158702
PubMed Web of Science ®Google Scholar
ColeAJDavidAEWangJGalbanCJHillHLYangVCPolyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targetingBiomaterials20113282183219321176955
PubMed Web of Science ®Google Scholar
KimCKKimJYKimJKParkJSByunYThe use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activatorBiomaterials200930295751575619656559
PubMed Web of Science ®Google Scholar
ImmordinoMLDosioFCattelLStealth liposomes: review of the basic science, rationale, and clinical applications, existing and potentialInt J Nanomedicine20061329731517717971
PubMed Web of Science ®Google Scholar
De ValeriolaDBrassinneCGaillardCStudy of excretion balance, metabolism and protein binding of 14C radiolabelled Taxotere (RP56976, NSC628503) in cancer patientsProc Am Cancer Res199334373
Google Scholar
HuynhLLerouxJCAllenCEnhancement of docetaxel solubility via conjugation of formulation-compatible moietiesOrg Biomol Chem20097173437344619675898
PubMed Web of Science ®Google Scholar
DongXWMattinglyCATsengMChoMAdamsVRMumperRJDevelopment of new lipid-based paclitaxel nanoparticles using sequential simplex optimizationEur J Pharm Biopharm200972191719111929
PubMed Web of Science ®Google Scholar
AnsellSMJohnstoneSATardiPGModulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugatesJ Med Chem200851113288329618465845
PubMed Web of Science ®Google Scholar
AliSAhmadIPetersAHydrolyzable hydrophobic taxanes: synthesis and anti-cancer activitiesAnticancer Drugs200112211712811261884
PubMed Web of Science ®Google Scholar
MumperRJDongXWMattinglyCADoxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATPCancer Res20096993918392619383919
PubMed Web of Science ®Google Scholar
AllenTMCullisPRDrug delivery systems: entering the mainstreamScience200430356651818182215031496
PubMed Web of Science ®Google Scholar
GardnerSNA mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugsCancer Res20006051417142510728708
PubMed Web of Science ®Google Scholar
DeutschHMGlinskiJAHernandezMSynthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activityJ Med Chem19893247887922564894
PubMed Web of Science ®Google Scholar
BradleyMOSwindellCSAnthonyFHTumor targeting by conjugation of DHA to paclitaxelJ Control Release2001741–323323611489499
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date